BeiGene
BGNE
#881
Rank
โ‚ฌ20.01 B
Marketcap
182,28ย โ‚ฌ
Share price
1.71%
Change (1 day)
0.79%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -โ‚ฌ0.82 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -โ‚ฌ0.8 B. In 2023 the company made an earning of -โ‚ฌ1.09 B an increase over its 2022 earnings that were of -โ‚ฌ1.62 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚ฌ0.82 B-25.16%
2023 -โ‚ฌ1.09 B-32.52%
2022 -โ‚ฌ1.62 B24.39%
2021 -โ‚ฌ1.3 B-13.21%
2020 -โ‚ฌ1.5 B72.69%
2019 -โ‚ฌ0.87 B36.01%
2018 -โ‚ฌ0.64 B616.83%
2017 -โ‚ฌ88.85 M-15.24%
2016 -โ‚ฌ0.11 B107.91%
2015 -โ‚ฌ50.42 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚ฌ16.39 M-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ0.23 B-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA